Thank You This PowerPoint document contains the images that you requested. Copyright Notice All Online Service materials, including, without limitation,

Slides:

Advertisements

Similar presentations

Thank You This PowerPoint document contains the images that you requested. Copyright Notice All Online Service materials, including, without limitation,

Advertisements

Thank You This PowerPoint document contains the images that you requested. Copyright Notice All Online Service materials, including, without limitation,

Thank You This PowerPoint document contains the images that you requested. Copyright Notice All Online Service materials, including, without limitation,

Thank You This PowerPoint document contains the images that you requested. Copyright Notice All Online Service materials, including, without limitation,

Thank You This PowerPoint document contains the images that you requested. Copyright Notice All Online Service materials, including, without limitation,

Thank You This PowerPoint document contains the images that you requested. Copyright Notice All Online Service materials, including, without limitation,

Thank You This PowerPoint document contains the images that you requested. Copyright Notice All Online Service materials, including, without limitation,

Thank You This PowerPoint document contains the images that you requested. Copyright Notice All Online Service materials, including, without limitation,

Thank You This PowerPoint document contains the images that you requested. Copyright Notice All Online Service materials, including, without limitation,

Thank You This PowerPoint document contains the images that you requested. Copyright Notice All Online Service materials, including, without limitation,

Thank You This PowerPoint document contains the images that you requested. Copyright Notice All Online Service materials, including, without limitation,

Thank You This PowerPoint document contains the images that you requested. Copyright Notice All Online Service materials, including, without limitation,

Thank You This PowerPoint document contains the images that you requested. Copyright Notice All Online Service materials, including, without limitation,

Thank You This PowerPoint document contains the images that you requested. Copyright Notice All Online Service materials, including, without limitation,

Thank You This PowerPoint document contains the images that you requested. Copyright Notice All Online Service materials, including, without limitation,

Thank You This PowerPoint document contains the images that you requested. Copyright Notice All Online Service materials, including, without limitation,

Thank You This PowerPoint document contains the images that you requested. Copyright Notice All Online Service materials, including, without limitation,

Thank You This PowerPoint document contains the images that you requested. Copyright Notice All Online Service materials, including, without limitation,

Thank You This PowerPoint document contains the images that you requested. Copyright Notice All Online Service materials, including, without limitation,

Thank You This PowerPoint document contains the images that you requested. Copyright Notice All Online Service materials, including, without limitation,

Thank You This PowerPoint document contains the images that you requested. Copyright Notice All Online Service materials, including, without limitation,

Thank You This PowerPoint document contains the images that you requested. Copyright Notice All Online Service materials, including, without limitation,

Thank You This PowerPoint document contains the images that you requested. Copyright Notice All Online Service materials, including, without limitation,

Thank You This PowerPoint document contains the images that you requested. Copyright Notice All Online Service materials, including, without limitation,

Thank You This PowerPoint document contains the images that you requested. Copyright Notice All Online Service materials, including, without limitation,

Thank You This PowerPoint document contains the images that you requested. Copyright Notice All Online Service materials, including, without limitation,

Thank You This PowerPoint document contains the images that you requested. Copyright Notice All Online Service materials, including, without limitation,

Thank You This PowerPoint document contains the images that you requested. Copyright Notice All Online Service materials, including, without limitation,

Thank You This PowerPoint document contains the images that you requested. Copyright Notice All Online Service materials, including, without limitation,

This PowerPoint document contains the images that you requested. Thank You Copyright Notice All materials on this Site are protected by United States copyright.

Biomarker analyses from a phase III, randomized, open-label, first-line study of gefitinib (G) versus carboplatin/paclitaxel (C/P)

Mok TS, Wu SL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361: Gefitinib Superior.

This PowerPoint document contains the images that you requested.

More of Kyle Singleton’s Graphic Design Work!

Volume 104, Pages (February 2017)

This PowerPoint document contains the images that you requested.

This PowerPoint document contains the images that you requested.

This PowerPoint document contains the images that you requested.

Title of Your Research Heading 3 Heading 6 Heading 4 Heading 1

TITLE Authors Institution

Figure 1 Rates of complications and mortality during index admission for atrial fibrillation ablation for the overall ... Figure 1 Rates of complications.

Figure 1 Data-selection process

Figure 1 Flow diagram detailing the systematic review process.

A Randomized Phase 2 Study Comparing the Combination of Ficlatuzumab and Gefitinib with Gefitinib Alone in Asian Patients with Advanced Stage Pulmonary.

(A) Mean (s.d.) ... (A) Mean (s.d.) baseline values for study variables for patients with and without tophi. (B) Baseline (s.d.) quality of life scores.

Figure 1 Mechanism of mortality benefit associated with radial access

Figure 1 The Kaplan–Meier curves of time to death post first hospitalization. hosp, hospitalization. Unless provided in the caption above, the following.

Figure 1. Serum ceftazidime concentrations following intravenous administration. Unless provided in the caption above, the following copyright applies.

Source: Figure created by the author based on data ...

Fig. 1 MRI aspect of an osteitis of the left acetabulum at baseline (A), 3 months (B), 1 year (C) and 2 years later, ... Fig. 1 MRI aspect of an osteitis.

Take home figure The protective role of CNP/NPR-B/NPRC.

Fig. 1 Flow chart of included patients for analyses

Fig. 1 Flow chart for selection of study subjects

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Figure 1. Relationships among microsatellite instability (MSI; letter A indicates the group with MSI), high tumour ... Figure 1. Relationships among microsatellite.

Figure 1. Trunk and leg fat over study period. LS, log transformed.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Fig. 1 Kaplan-Meier plot presenting no difference in progression to RA in patients with clinically suspect ... Fig. 1 Kaplan-Meier plot presenting no difference.

Figure 1. Oncoprint of selected pathogenic alterations detected in ctDNA. Unless provided in the caption above, the following copyright applies to the.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Figure 1 Patient selection

Figure 1 Grant agencies and charitable foundations supporting Plan S.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Figure 3. Key words and phrases from narrative text by classification category. Unless provided in the caption above, the following copyright applies to.

Figure 1 ABCDE of primary prevention.2

Figure 1. Forest plot of lung cancer mortality in LDCT trials.

Table 2. Mean noise level results for hand dryers in dBA

Figure 1. Overall response rates in wild-type versus RAS and RAS/BRAF mutations detected by nanofluidic digital PCR ... Figure 1. Overall response rates.

This PowerPoint document contains the images that you requested.

Presentation transcript:

Thank You This PowerPoint document contains the images that you requested. Copyright Notice All Online Service materials, including, without limitation, text, pictures, graphics and other files and the selection and arrangement thereof are copyrighted materials of Ovid or its licensors, all rights reserved. Except for the Authorized Use specified above, you may not copy, modify or distribute any of the Online Service materials. You may not "mirror" any material contained on this Online Service on any other server. Any unauthorized use of any material contained on this Online Service may violate copyright laws, trademark laws, the laws of privacy and publicity and communications regulations and statutes.

Copyright © 2009 Massachusetts Medical Society. All rights reserved. Published by Massachusetts Medical Society. 2 Supplemental Supplement to: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. Mok, T; Wu, Y-L; Thongprasert, S New England Journal of Medicine. 361(10), September 3, Supplemental Table 1. Key Demographic and Baseline Characteristics for Patients by EGFR Mutation Status

Copyright © 2009 Massachusetts Medical Society. All rights reserved. Published by Massachusetts Medical Society. 3 Supplemental Supplement to: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. Mok, T; Wu, Y-L; Thongprasert, S New England Journal of Medicine. 361(10), September 3, Supplemental Table 2. Baseline EGFR Mutation Status.

Copyright © 2009 Massachusetts Medical Society. All rights reserved. Published by Massachusetts Medical Society. 4 Supplemental Supplement to: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. Mok, T; Wu, Y-L; Thongprasert, S New England Journal of Medicine. 361(10), September 3, Supplemental Table 3. Best Overall Response in the Overall Population, EGFR Mutation-Positive Patients, EGFR Mutation-Negative Patients, and Patients with Unknown EGFR Mutation Status (ITT Population).

Copyright © 2009 Massachusetts Medical Society. All rights reserved. Published by Massachusetts Medical Society. 5 Supplement to: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. Mok, T; Wu, Y-L; Thongprasert, S New England Journal of Medicine. 361(10), September 3, Supplemental Table 3. No caption available.

Copyright © 2009 Massachusetts Medical Society. All rights reserved. Published by Massachusetts Medical Society. 6 Supplement to: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. Mok, T; Wu, Y-L; Thongprasert, S New England Journal of Medicine. 361(10), September 3, Supplemental Table 3. No caption available.

Copyright © 2009 Massachusetts Medical Society. All rights reserved. Published by Massachusetts Medical Society. 7 Supplemental Supplement to: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. Mok, T; Wu, Y-L; Thongprasert, S New England Journal of Medicine. 361(10), September 3, Supplemental Figure 1.

Copyright © 2009 Massachusetts Medical Society. All rights reserved. Published by Massachusetts Medical Society. 8 Supplemental Supplement to: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. Mok, T; Wu, Y-L; Thongprasert, S New England Journal of Medicine. 361(10), September 3, Supplemental Figure 2.

Copyright © 2009 Massachusetts Medical Society. All rights reserved. Published by Massachusetts Medical Society. 9 Supplemental Supplement to: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. Mok, T; Wu, Y-L; Thongprasert, S New England Journal of Medicine. 361(10), September 3, Supplemental Figure 3